Byetta's US label updated to warn of renal failure
This article was originally published in Scrip
Executive Summary
The US FDA has notified healthcare professionals of the label changes for Amylin/Lilly's diabetes drug Byetta (exenatide) to reflect postmarketing reports of altered kidney function, including acute renal failure and insufficiency.